A Phase 3, randomized study of first-line durvalumab (D) plus /- tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): CASPIAN

被引：0
|
作者：
Alt, J. [1 ]
Bischoff, H. G. [2 ]
Laack, H-E [3 ]
Leistner, R. D. [4 ]
Panse, J. [5 ]
Reinmuth, N. [6 ]
Schulz, C. [7 ]
Grohe, C. [8 ]
机构：
[1] Univ Med Mainz, Mainz, Germany
[2] Univ Hosp Heidelberg, Thoraxklin Heidelberg, Heidelberg, Germany
[3] Hamatol Onkol Hamburg, Hamburg, Germany
[4] Sozialstiftung Bamberg, Med Klin Pneumol Allergol & Schlafmed 4, Bamberg, Germany
[5] RWTH Aachen Univ Hosp, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany
[6] Asklepios Fachkliniken Gauting, Onkol Klin Pneumol, Gauting, Germany
[7] Klinikum Univ Regensburg, Med Klin & Poliklin 2, Regensburg, Germany
[8] Evangel Lungenklin Berlin Krankenhausbetriebs gGm, Klin Pneumol, Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [41] MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
    Peters, S.
    Antonia, S.
    Goldberg, S. B.
    Heymach, J. V.
    Kim, E. S.
    Nakagawa, K.
    Papadimitrakopoulou, V.
    Mukhopadhyay, P.
    McIntosh, S.
    Rizvi, N. A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S139 - S140
  • [42] Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer
    Huang, Y.
    Tong, F.
    Zhang, R.
    Liu, P.
    Dong, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S704 - S705
  • [43] DURVALUMAB (D) ± TREMELIMUMAB (T) plus PLATINUMETOPOSIDE (EP) IN EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC): RNA SEQUENCING ANALYSIS TO EXPLORE CANONICAL MARKERS OF IO ACTIVITY IN CASPIAN
    Xie, Mingchao
    Chugh, Priti
    O'Brien, Cathy
    Lai, Zhongwu
    Stewart, Ross
    Paz-Ares, Luis
    Goldman, Jonathan
    Garassino, Marina
    Rudin, Charles
    Barrett, J. Carl
    Shrestha, Yashaswi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A613 - A613
  • [44] First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
    Liu, Wenjie
    Huo, Gengwei
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [45] Thoracic radiotherapy plus maintenance durvalumab after first-line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC): A multicenter single-arm open-label phase II trial (SAKK 15/19)tle
    Addeo, A.
    Dietrich, D.
    Mach, N.
    Mark, M. T.
    Joerger, M.
    Froesch, P. R.
    De Nicola, L. Wannesson
    Konig, D.
    Fernandez, E.
    Patzen, A.
    Vees, H.
    Picardi, C.
    Frueh, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1065 - S1065
  • [46] Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
    Goldman, Jonathan W.
    Garassino, Marina Chiara
    Chen, Yuanbin
    Ozguroglu, Mustafa
    Dvorkin, Mikhail
    Trukhin, Dmytro
    Statsenko, Galina
    Hotta, Katsuyuki
    Ji, Jun Ho
    Hochmair, Maximilian J.
    Voitko, Oleksandr
    Havel, Libor
    Poltoratskiy, Artem
    Losonczy, Gyorgy
    Reinmuth, Niels
    Patel, Nikunj
    Laud, Peter J.
    Shire, Norah
    Jiang, Haiyi
    Paz-Ares, Luis
    LUNG CANCER, 2020, 149 : 46 - 52
  • [47] A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC)
    Glisson, Bonnie
    Kazarnowicz, Andrzej
    Nackaerts, Kristiaan
    Orlov, Sergey
    Ramlau, Rodryg
    Besse, Benjamin
    Cobo Dols, Manuel
    Menon, Hari
    Paz-Ares Rodriguez, Luis
    Zhang, Yilong
    Zhu, Min
    Jiang, Yizhou
    Loh, Elwyn
    Gansert, Jennifer
    Dubey, Sarita
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S220 - S221
  • [48] KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)
    Rudin, C. M.
    Shen, L.
    Pietanza, M. C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Phase IIIb study of durvalumab plus platinumeetoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab
    Isla, D.
    Arriola, E.
    Garcia Campelo, M. R.
    Marti, C.
    Diz Tain, P.
    Moreno Vega, A. L.
    Piqueras, M. L-B.
    Leon, L.
    Gutierrez Calderon, V.
    Oramas Rodriguez, J. M.
    Majem, M.
    Sanchez-Hernandez, A.
    Aguado de la Rosa, C.
    Alvarez Cabellos, R.
    Marti-Ciriquian, J. L.
    Moreno Paul, A.
    Gonzalez Cordero, M.
    Callejo Mellen, A.
    Baez, L.
    Zugazagoitia, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S98 - S99
  • [50] Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.
    Chen, Lijuan
    Zhao, Yanqiu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345